IBPClin - Instituto Brasil de Pesquisa Clínica

Rio de Janeiro, Rio de Janeiro 20241-180

1 studies enrolling now · 2 studies all time

What they study most

Atopic Dermatitis, COVID-19, Eczema

Studies at this site

• A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis — Enrolling by invitation
• Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR). — Stopped early